Clinical Innovations, Inc.

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Depression5 trials
• Schizophrenia3 trials
• Bipolar disorder1 trial

Phase

• Phase 36 trials
• Phase 22 trials

Status

• Completed5 trials
• Active, not recruiting3 trials

Lead sponsor

• Boehringer Ingelheim2 trials
• Xenon Pharmaceuticals Inc.2 trials
• COMPASS Pathways1 trial
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial
• and 1 more

Running trials

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

  NCT07172516· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  NCT07076407· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

Closed trials

• Completed

  A Study to Test Different Doses of BI 1569912 in People With Depression

  NCT06558344· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

  NCT06126497· Phase 2· Suven Life Sciences Limited· Source

• Completed

  A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

  NCT05628103· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source